COL 177
Alternative Names: COL-177Latest Information Update: 04 Nov 2017
At a glance
- Originator Onset Therapeutics
- Developer Onset Dermatologics
- Class Anti-inflammatories; Antiacnes
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acne vulgaris
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Acne-vulgaris in USA (Topical, Foam)
- 29 Jan 2010 Clinical trials in Acne vulgaris in USA (Topical)